top of page

Biogen and Ionis’ spinal muscular atrophy treatment meets primary endpoint in phase 3 study

Biogen and Ionis Pharmaceuticals said that Spinraza (nusinersen), an investigational treatment for spinal muscular atrophy (SMA), has met the primary endpoint in a phase 3 trial.




Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page